StockNews.com upgraded shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) from a buy rating to a strong-buy rating in a research note released on Friday. Several other equities analysts have also recently issued reports on VRTX. Royal Bank of Canada boosted their price objective on Vertex Pharmaceuticals from $397.00 to $420.00 and gave the company […]